Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

Priscilla Wander; Laurence C. Cheung; Sandra S. Pinhanҫos; Luke Jones; Mark Kerstjens; Susan T.C.J.M. Arentsen-Peters; Sajla Singh; Grace Alyssa Chua; Patricia Garrido Castro; Pauline Schneider; M. Emmy M. Dolman; Bianca Koopmans; Jan J. Molenaar; Rob Pieters; C. Michel Zwaan; Rishi S. Kotecha; Ronald W. Stam

doi:10.1038/s41375-020-0895-9

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

Priscilla Wander, Laurence C. Cheung, Sandra S. Pinhanҫos, Luke Jones, Mark Kerstjens, Susan T.C.J.M. Arentsen-Peters, Sajla Singh, Grace Alyssa Chua, Patricia Garrido Castro, Pauline Schneider, M. Emmy M. Dolman, Bianca Koopmans, Jan J. Molenaar, Rob Pieters, C. Michel Zwaan, Rishi S. Kotecha, Ronald W. Stam

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

4 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	2898-2902
Aantal pagina's	5
Tijdschrift	Leukemia
Volume	34
Nummer van het tijdschrift	11
DOI's	https://doi.org/10.1038/s41375-020-0895-9
Status	Gepubliceerd - 1 nov. 2020

Toegang tot document

10.1038/s41375-020-0895-9

Citeer dit

Wander, P., Cheung, L. C., Pinhanҫos, S. S., Jones, L., Kerstjens, M., Arentsen-Peters, S. T. C. J. M., Singh, S., Chua, G. A., Castro, P. G., Schneider, P., Dolman, M. E. M., Koopmans, B., Molenaar, J. J., Pieters, R., Zwaan, C. M., Kotecha, R. S., & Stam, R. W. (2020). Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia, 34(11), 2898-2902. https://doi.org/10.1038/s41375-020-0895-9

@article{6afb07eae0c7449bb314fb5b90a3ff1d,

title = "Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia",

keywords = "Animals, Antimetabolites, Antineoplastic/pharmacology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Deoxycytidine/analogs & derivatives, Disease Management, Disease Models, Animal, Drug Evaluation, Preclinical, Gene Rearrangement, Genetic Predisposition to Disease, Humans, Infant, Myeloid-Lymphoid Leukemia Protein/genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Gemcitabine",

author = "Priscilla Wander and Cheung, {Laurence C.} and Pinhanҫos, {Sandra S.} and Luke Jones and Mark Kerstjens and Arentsen-Peters, {Susan T.C.J.M.} and Sajla Singh and Chua, {Grace Alyssa} and Castro, {Patricia Garrido} and Pauline Schneider and Dolman, {M. Emmy M.} and Bianca Koopmans and Molenaar, {Jan J.} and Rob Pieters and Zwaan, {C. Michel} and Kotecha, {Rishi S.} and Stam, {Ronald W.}",

note = "Funding Information: Acknowledgements RSK is supported by a Fellowship from the National Health and Medical Research Council of Australia (NHMRC APP1142627). RSK and LCC are supported by the Children{\textquoteright}s Leukaemia and Cancer Research Foundation (CLCRF, Australia).",

year = "2020",

month = nov,

day = "1",

doi = "10.1038/s41375-020-0895-9",

language = "English",

volume = "34",

pages = "2898--2902",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

Wander, P, Cheung, LC, Pinhanҫos, SS, Jones, L, Kerstjens, M, Arentsen-Peters, STCJM, Singh, S, Chua, GA, Castro, PG, Schneider, P , Dolman, MEM, Koopmans, B, Molenaar, JJ , Pieters, R , Zwaan, CM, Kotecha, RS & Stam, RW 2020, 'Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia', Leukemia, vol. 34, nr. 11, blz. 2898-2902. https://doi.org/10.1038/s41375-020-0895-9

TY - JOUR

T1 - Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

AU - Wander, Priscilla

AU - Cheung, Laurence C.

AU - Pinhanҫos, Sandra S.

AU - Jones, Luke

AU - Kerstjens, Mark

AU - Arentsen-Peters, Susan T.C.J.M.

AU - Singh, Sajla

AU - Chua, Grace Alyssa

AU - Castro, Patricia Garrido

AU - Schneider, Pauline

AU - Dolman, M. Emmy M.

AU - Koopmans, Bianca

AU - Molenaar, Jan J.

AU - Pieters, Rob

AU - Zwaan, C. Michel

AU - Kotecha, Rishi S.

AU - Stam, Ronald W.

N1 - Funding Information: Acknowledgements RSK is supported by a Fellowship from the National Health and Medical Research Council of Australia (NHMRC APP1142627). RSK and LCC are supported by the Children’s Leukaemia and Cancer Research Foundation (CLCRF, Australia).

PY - 2020/11/1

Y1 - 2020/11/1

KW - Animals

KW - Antimetabolites, Antineoplastic/pharmacology

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Deoxycytidine/analogs & derivatives

KW - Disease Management

KW - Disease Models, Animal

KW - Drug Evaluation, Preclinical

KW - Gene Rearrangement

KW - Genetic Predisposition to Disease

KW - Humans

KW - Infant

KW - Myeloid-Lymphoid Leukemia Protein/genetics

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

KW - Gemcitabine

UR - http://www.scopus.com/inward/record.url?scp=85085769393&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0895-9

DO - 10.1038/s41375-020-0895-9

M3 - Article

C2 - 32488115

AN - SCOPUS:85085769393

SN - 0887-6924

VL - 34

SP - 2898

EP - 2902

JO - Leukemia

JF - Leukemia

IS - 11

ER -